Gencurix Decides to Merge with 1.7 Billion Won Liquid Biopsy Venture 'Genopix'

KOSDAQ-listed company Gencurix (CEO Cho Sang-rae) announced on the 25th that it will absorb and merge with the unlisted bio venture Genopix for a scale of a total of 1.77375 billion won (valuation of the disappearing company). This merger will proceed in the form of a small-scale merger, and after the merger, Gencurix will survive and Genopix will be dissolved.

The merger ratio between the two companies is 1 : 5.3591461, and the merger value was calculated at 2,389 won per share for Gencurix and 12,803 won per share for Genopix, respectively. In consideration for this merger, Gencurix plans to issue 742,456 shares of new common stock and distribute them to Genopix shareholders, and these new merger shares will be locked up for one year after listing.

The merged company, Genopix, is a liquid biopsy-based genomic and protein analysis solution company. It is currently in the development stage with no recent sales (2025 to Q1 2026) due to a lack of production track record for commercialized products, but it is an R&D-centric bio company that was highly evaluated for its earnings value (19,789 won per share) based on its future technological prowess. As of the end of the most recent business year, its total assets are 203.38 million won, and its total equity is 188.45 million won.

Through this merger, Gencurix will fully secure the liquid biopsy analysis method development know-how and clinical data held by Genopix. The company plans to utilize this to strengthen its R&D capabilities, such as improving products currently under research and development and expanding new pipelines, and to enhance market competitiveness by sharing its network of medical professionals.

Meanwhile, this merger is being pursued as a small-scale merger structure under the Commercial Act, so the approval of the general shareholders' meeting will be replaced by the approval of the board of directors (scheduled for July 28), and appraisal rights will not be recognized. The merger date is September 1, 2026, and the expected listing date of the new shares is September 23.